Date: Tuesday 2nd July 2024 Time: 14:00-15:30 BST | 15:00-16:30 CEST Location: Online via Zoom Speakers: Rachid Abbas, Angeliki Thanasopoulou, and Marcel Wolbers (Roche).
Who is this event intended for? Clinicians, Regulators, Investigators, Academics, members of Ethics Committees, Health technology assessors, Statisticians. What is the benefit of attending?
● To illustrate the purpose of each estimand attributes using simple language in a pivotal study in early Alzheimer's disease
● Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of a clinical trial, in order to:
- gain alignment on the question(s) of interest
- frame questions which may be of interest to different stakeholders
- be transparent when communicating trial results
Registration
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
Overview
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.
In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.
This webinar will be interactive. Questions will be raised at different points during the talk and we will end with 30 minutes dedicated to answer open questions.
Speaker details
Speaker
Biography
Rachid Abbas
Rachid Abbas is a statistician in Roche's Product Development department since 2020.
With a medical degree in public health and a Master’s in biostatistics, he has a strong interest in statistical issues in drug development. Rachid has held academic positions at Paris Diderot University and Gustave Roussy, contributing to clinical trials in geriatrics and neuro-oncology. At Roche, he supports late-phase Alzheimer's Disease programs. His research interests include the design and analysis of innovative clinical trials, including adaptive designs, estimands, and trial emulation.
Angeliki Thanaspoulou
Angeliki is a Senior Clinical Scientist in the Alzheimer’s Disease & Neurodegeneration Franchise at Roche since 2019.
She has previously worked in clinical development in a small size biotech focusing on rare diseases in neuromuscular, neurodegenerative and respiratory indications, across Phase 1 up to Phase 4 studies. Prior to joining the Pharmaceutical Industry she completed a postdoctoral position in the University Hospital Basel working on translational research and Investigator Initiated Trials. Angeliki is a biologist in training with a masters and PhD in molecular and cellular biology.
Marcel Wolbers
Since completing his PhD in mathematical statistics in 2002, Marcel Wolbers has spent half of his career as an academic biostatistician and the other half as a statistician in the pharmaceutical industry. Between 2009 and 2016, he was the head of biostatistics at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Since 2016, he has been an expert statistician working in the Methods, Collaboration, and Outreach group (MCO) of Roche's data sciences and statistics department. His research interests include the design and analysis of innovative clinical trials, estimands, missing data, prognostic models, and competing risks.
Scientific Meetings
PSI EIWG Webinar: Estimands framework in action, the Alzheimer's disease case
Date: Tuesday 2nd July 2024 Time: 14:00-15:30 BST | 15:00-16:30 CEST Location: Online via Zoom Speakers: Rachid Abbas, Angeliki Thanasopoulou, and Marcel Wolbers (Roche).
Who is this event intended for? Clinicians, Regulators, Investigators, Academics, members of Ethics Committees, Health technology assessors, Statisticians. What is the benefit of attending?
● To illustrate the purpose of each estimand attributes using simple language in a pivotal study in early Alzheimer's disease
● Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of a clinical trial, in order to:
- gain alignment on the question(s) of interest
- frame questions which may be of interest to different stakeholders
- be transparent when communicating trial results
Registration
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
Overview
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.
In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.
This webinar will be interactive. Questions will be raised at different points during the talk and we will end with 30 minutes dedicated to answer open questions.
Speaker details
Speaker
Biography
Rachid Abbas
Rachid Abbas is a statistician in Roche's Product Development department since 2020.
With a medical degree in public health and a Master’s in biostatistics, he has a strong interest in statistical issues in drug development. Rachid has held academic positions at Paris Diderot University and Gustave Roussy, contributing to clinical trials in geriatrics and neuro-oncology. At Roche, he supports late-phase Alzheimer's Disease programs. His research interests include the design and analysis of innovative clinical trials, including adaptive designs, estimands, and trial emulation.
Angeliki Thanaspoulou
Angeliki is a Senior Clinical Scientist in the Alzheimer’s Disease & Neurodegeneration Franchise at Roche since 2019.
She has previously worked in clinical development in a small size biotech focusing on rare diseases in neuromuscular, neurodegenerative and respiratory indications, across Phase 1 up to Phase 4 studies. Prior to joining the Pharmaceutical Industry she completed a postdoctoral position in the University Hospital Basel working on translational research and Investigator Initiated Trials. Angeliki is a biologist in training with a masters and PhD in molecular and cellular biology.
Marcel Wolbers
Since completing his PhD in mathematical statistics in 2002, Marcel Wolbers has spent half of his career as an academic biostatistician and the other half as a statistician in the pharmaceutical industry. Between 2009 and 2016, he was the head of biostatistics at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Since 2016, he has been an expert statistician working in the Methods, Collaboration, and Outreach group (MCO) of Roche's data sciences and statistics department. His research interests include the design and analysis of innovative clinical trials, estimands, missing data, prognostic models, and competing risks.
Training Courses
PSI EIWG Webinar: Estimands framework in action, the Alzheimer's disease case
Date: Tuesday 2nd July 2024 Time: 14:00-15:30 BST | 15:00-16:30 CEST Location: Online via Zoom Speakers: Rachid Abbas, Angeliki Thanasopoulou, and Marcel Wolbers (Roche).
Who is this event intended for? Clinicians, Regulators, Investigators, Academics, members of Ethics Committees, Health technology assessors, Statisticians. What is the benefit of attending?
● To illustrate the purpose of each estimand attributes using simple language in a pivotal study in early Alzheimer's disease
● Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of a clinical trial, in order to:
- gain alignment on the question(s) of interest
- frame questions which may be of interest to different stakeholders
- be transparent when communicating trial results
Registration
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
Overview
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.
In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.
This webinar will be interactive. Questions will be raised at different points during the talk and we will end with 30 minutes dedicated to answer open questions.
Speaker details
Speaker
Biography
Rachid Abbas
Rachid Abbas is a statistician in Roche's Product Development department since 2020.
With a medical degree in public health and a Master’s in biostatistics, he has a strong interest in statistical issues in drug development. Rachid has held academic positions at Paris Diderot University and Gustave Roussy, contributing to clinical trials in geriatrics and neuro-oncology. At Roche, he supports late-phase Alzheimer's Disease programs. His research interests include the design and analysis of innovative clinical trials, including adaptive designs, estimands, and trial emulation.
Angeliki Thanaspoulou
Angeliki is a Senior Clinical Scientist in the Alzheimer’s Disease & Neurodegeneration Franchise at Roche since 2019.
She has previously worked in clinical development in a small size biotech focusing on rare diseases in neuromuscular, neurodegenerative and respiratory indications, across Phase 1 up to Phase 4 studies. Prior to joining the Pharmaceutical Industry she completed a postdoctoral position in the University Hospital Basel working on translational research and Investigator Initiated Trials. Angeliki is a biologist in training with a masters and PhD in molecular and cellular biology.
Marcel Wolbers
Since completing his PhD in mathematical statistics in 2002, Marcel Wolbers has spent half of his career as an academic biostatistician and the other half as a statistician in the pharmaceutical industry. Between 2009 and 2016, he was the head of biostatistics at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Since 2016, he has been an expert statistician working in the Methods, Collaboration, and Outreach group (MCO) of Roche's data sciences and statistics department. His research interests include the design and analysis of innovative clinical trials, estimands, missing data, prognostic models, and competing risks.
Journal Club
PSI EIWG Webinar: Estimands framework in action, the Alzheimer's disease case
Date: Tuesday 2nd July 2024 Time: 14:00-15:30 BST | 15:00-16:30 CEST Location: Online via Zoom Speakers: Rachid Abbas, Angeliki Thanasopoulou, and Marcel Wolbers (Roche).
Who is this event intended for? Clinicians, Regulators, Investigators, Academics, members of Ethics Committees, Health technology assessors, Statisticians. What is the benefit of attending?
● To illustrate the purpose of each estimand attributes using simple language in a pivotal study in early Alzheimer's disease
● Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of a clinical trial, in order to:
- gain alignment on the question(s) of interest
- frame questions which may be of interest to different stakeholders
- be transparent when communicating trial results
Registration
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
Overview
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.
In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.
This webinar will be interactive. Questions will be raised at different points during the talk and we will end with 30 minutes dedicated to answer open questions.
Speaker details
Speaker
Biography
Rachid Abbas
Rachid Abbas is a statistician in Roche's Product Development department since 2020.
With a medical degree in public health and a Master’s in biostatistics, he has a strong interest in statistical issues in drug development. Rachid has held academic positions at Paris Diderot University and Gustave Roussy, contributing to clinical trials in geriatrics and neuro-oncology. At Roche, he supports late-phase Alzheimer's Disease programs. His research interests include the design and analysis of innovative clinical trials, including adaptive designs, estimands, and trial emulation.
Angeliki Thanaspoulou
Angeliki is a Senior Clinical Scientist in the Alzheimer’s Disease & Neurodegeneration Franchise at Roche since 2019.
She has previously worked in clinical development in a small size biotech focusing on rare diseases in neuromuscular, neurodegenerative and respiratory indications, across Phase 1 up to Phase 4 studies. Prior to joining the Pharmaceutical Industry she completed a postdoctoral position in the University Hospital Basel working on translational research and Investigator Initiated Trials. Angeliki is a biologist in training with a masters and PhD in molecular and cellular biology.
Marcel Wolbers
Since completing his PhD in mathematical statistics in 2002, Marcel Wolbers has spent half of his career as an academic biostatistician and the other half as a statistician in the pharmaceutical industry. Between 2009 and 2016, he was the head of biostatistics at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Since 2016, he has been an expert statistician working in the Methods, Collaboration, and Outreach group (MCO) of Roche's data sciences and statistics department. His research interests include the design and analysis of innovative clinical trials, estimands, missing data, prognostic models, and competing risks.
Webinars
PSI EIWG Webinar: Estimands framework in action, the Alzheimer's disease case
Date: Tuesday 2nd July 2024 Time: 14:00-15:30 BST | 15:00-16:30 CEST Location: Online via Zoom Speakers: Rachid Abbas, Angeliki Thanasopoulou, and Marcel Wolbers (Roche).
Who is this event intended for? Clinicians, Regulators, Investigators, Academics, members of Ethics Committees, Health technology assessors, Statisticians. What is the benefit of attending?
● To illustrate the purpose of each estimand attributes using simple language in a pivotal study in early Alzheimer's disease
● Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of a clinical trial, in order to:
- gain alignment on the question(s) of interest
- frame questions which may be of interest to different stakeholders
- be transparent when communicating trial results
Registration
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
Overview
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.
In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.
This webinar will be interactive. Questions will be raised at different points during the talk and we will end with 30 minutes dedicated to answer open questions.
Speaker details
Speaker
Biography
Rachid Abbas
Rachid Abbas is a statistician in Roche's Product Development department since 2020.
With a medical degree in public health and a Master’s in biostatistics, he has a strong interest in statistical issues in drug development. Rachid has held academic positions at Paris Diderot University and Gustave Roussy, contributing to clinical trials in geriatrics and neuro-oncology. At Roche, he supports late-phase Alzheimer's Disease programs. His research interests include the design and analysis of innovative clinical trials, including adaptive designs, estimands, and trial emulation.
Angeliki Thanaspoulou
Angeliki is a Senior Clinical Scientist in the Alzheimer’s Disease & Neurodegeneration Franchise at Roche since 2019.
She has previously worked in clinical development in a small size biotech focusing on rare diseases in neuromuscular, neurodegenerative and respiratory indications, across Phase 1 up to Phase 4 studies. Prior to joining the Pharmaceutical Industry she completed a postdoctoral position in the University Hospital Basel working on translational research and Investigator Initiated Trials. Angeliki is a biologist in training with a masters and PhD in molecular and cellular biology.
Marcel Wolbers
Since completing his PhD in mathematical statistics in 2002, Marcel Wolbers has spent half of his career as an academic biostatistician and the other half as a statistician in the pharmaceutical industry. Between 2009 and 2016, he was the head of biostatistics at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Since 2016, he has been an expert statistician working in the Methods, Collaboration, and Outreach group (MCO) of Roche's data sciences and statistics department. His research interests include the design and analysis of innovative clinical trials, estimands, missing data, prognostic models, and competing risks.
Careers Meetings
PSI EIWG Webinar: Estimands framework in action, the Alzheimer's disease case
Date: Tuesday 2nd July 2024 Time: 14:00-15:30 BST | 15:00-16:30 CEST Location: Online via Zoom Speakers: Rachid Abbas, Angeliki Thanasopoulou, and Marcel Wolbers (Roche).
Who is this event intended for? Clinicians, Regulators, Investigators, Academics, members of Ethics Committees, Health technology assessors, Statisticians. What is the benefit of attending?
● To illustrate the purpose of each estimand attributes using simple language in a pivotal study in early Alzheimer's disease
● Recognize the benefits of following the estimand framework (ICH E9 (R1) addendum) in the context of a clinical trial, in order to:
- gain alignment on the question(s) of interest
- frame questions which may be of interest to different stakeholders
- be transparent when communicating trial results
Registration
This event is free to both Members of PSI and Non-Members. To register your place for this event, please click here.
Overview
The webinar will show how the estimand framework was applied in a Phase 3 trial in Alzheimer's disease.
GRADUATE I(NCT03444870) and GRADUATE II (NCT03443973) were two global, Phase III, randomized, placebo-controlled trials assessing the efficacy and safety of gantenerumab in early Alzheimer's disease. The GRADUATE studies were among the first pivotal trials in Alzheimer's Disease to adopt the estimand framework and to conduct a primary analysis which is fully aligned with the targeted estimand.
In this webinar we will review the key elements of the estimand framework through the experience of the Graduate study team. We will review how the Graduate study team interpreted the estimand framework and used its elements to cover the primary clinical question of interest. We will review the challenges we met and the solutions we implemented.
This webinar will be interactive. Questions will be raised at different points during the talk and we will end with 30 minutes dedicated to answer open questions.
Speaker details
Speaker
Biography
Rachid Abbas
Rachid Abbas is a statistician in Roche's Product Development department since 2020.
With a medical degree in public health and a Master’s in biostatistics, he has a strong interest in statistical issues in drug development. Rachid has held academic positions at Paris Diderot University and Gustave Roussy, contributing to clinical trials in geriatrics and neuro-oncology. At Roche, he supports late-phase Alzheimer's Disease programs. His research interests include the design and analysis of innovative clinical trials, including adaptive designs, estimands, and trial emulation.
Angeliki Thanaspoulou
Angeliki is a Senior Clinical Scientist in the Alzheimer’s Disease & Neurodegeneration Franchise at Roche since 2019.
She has previously worked in clinical development in a small size biotech focusing on rare diseases in neuromuscular, neurodegenerative and respiratory indications, across Phase 1 up to Phase 4 studies. Prior to joining the Pharmaceutical Industry she completed a postdoctoral position in the University Hospital Basel working on translational research and Investigator Initiated Trials. Angeliki is a biologist in training with a masters and PhD in molecular and cellular biology.
Marcel Wolbers
Since completing his PhD in mathematical statistics in 2002, Marcel Wolbers has spent half of his career as an academic biostatistician and the other half as a statistician in the pharmaceutical industry. Between 2009 and 2016, he was the head of biostatistics at the Oxford University Clinical Research Unit in Ho Chi Minh City, Vietnam. Since 2016, he has been an expert statistician working in the Methods, Collaboration, and Outreach group (MCO) of Roche's data sciences and statistics department. His research interests include the design and analysis of innovative clinical trials, estimands, missing data, prognostic models, and competing risks.
Upcoming Events
PSI Training Course: Effective Leadership – the keys to growing your leadership capabilities
This course will consist of three online half-day workshops. The first will be aimed at building trust, the backbone of leadership and a key to becoming effective. This is key to building a solid foundation.
The second will be on improving communication as a technical leader. This workshop will focus on communication strategies for different stakeholders and will involve tips on effective communication and how to develop the skills of active listening, coaching and what improv can teach us about good communication.
The final workshop will bring these two components together to help leaders become more influential. This will also focus on how to use Steven Covey’s 7-Habits, in particular Habits 4, 5 and 6, which are called the habits of communication.
The workshops will be interactive, allowing you to practice the concepts discussed. There will be plenty of time for questions and discussion. There will also be reflective time where you can think about what you are learning and how you might experiment with it.
PSI Introduction to Industry Training (ITIT) Course - 2026/2027
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This webinar brings together three bitesize complementary sessions to help PSI contributors create conference presentations and posters that communicate clearly and inclusively. Participants will explore how to refine their message, prepare materials effectively, and adopt practical habits that support confident, accessible delivery. A focused, supportive session designed to elevate every contribution.
Our monthly webinar series allows attendees to gain practical knowledge and skills in open-source coding and tools, with a focus on applications in the pharmaceutical industry. This month’s session, “Graphics Basics,” will introduce the fundamentals of producing graphics using the ggplot2 package.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Join our Health Technology Assessment (HTA) European Special Interest Group (ESIG) for a webinar on the strategic role of statisticians in the Joint Clinical Assessment (JCA). The introduction of the JCA marks a new era for evidence generation and market access in Europe. As HTA requirements become more harmonized and methodologically demanding, the role of statisticians has evolved far beyond data analysis. Today, statistical expertise is central to shaping clinical development strategies, designing robust comparative evidence, and ensuring that submissions withstand the scrutiny of EU-level assessors. In this webinar, we explore how statisticians contribute strategically to successful JCA outcomes.
Statisticians in the Age of AI: On Route to Strategic Partnership
A 90-minute webinar featuring two case studies from Bayer and Roche demonstrating how statisticians successfully integrated into AI programs, followed by interactive discussion on strategies for elevating statistical expertise in the AI era.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
GSK - Statistics Director - Vaccines and Infectious Disease
We are seeking an experienced and visionary Statistics Director to join our Team and lead strategic statistical innovation across GSK’s Vaccines and Infectious Disease portfolio.
As a Senior Biostatistician I at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.
As a Statistical Scientist at ICON, you will play a pivotal role in designing and analyzing clinical trials, interpreting complex medical data, and contributing to the advancement of innovative treatments and therapies.
We have an exciting opportunity for an Associate Director, Biostatistics to join a passionate team within Advanced Quantitative Sciences – Full Development.
: We have an exciting opportunity for an Associate Director (AD), Statistical Programming, to join a passionate team within Advanced Quantitative Sciences- Development.
Novartis - Senior Principal Statistical Programmer
We have an exciting opportunity for a Senior Principal Statistical Programmer, to join a passionate team within Advanced Quantitative Sciences – Development.
Pierre Fabre - Clinical Development Safety Statistics Expert M/F
We are seeking a highly skilled and proactive Clinical Development Safety Statistics Expert to join our Biometry Department and the Biometry Leadership Team based in Toulouse (31, Oncopole) or Boulogne (92).
Pierre Fabre - Lead Statistician – Real World Evidence -CDI- M/F
Pierre Fabre Laboratories are hiring a highly skilled and experienced Lead Statistician – Real World Evidence (RWE) to join the Biometry Department, part of the Data Science & Biometry Department, based in Toulouse (Oncopôle) or Boulogne.
Pierre Fabre - Lead Statistician- Clinical Trials M/F
We are seeking a highly skilled and experienced Lead Statistician in Clinical Trials to join our Biometry Department based in Toulouse (31, Oncopole) or Boulogne (92).
We are looking for Senior Statistical Programmers in the UK to join Veramed, where you'll deliver high-impact programming solutions in an FSP-style capacity, while advancing your career in a supportive, growth-driven environment.
